GlassScriptPhysician profile
Jose R Ordonez
NPI 1154323871
$5,716.62
in general payments reported to CMS, 2019-2025
27 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $759 · 2021: $1,389 · 2022: $651 · 2023: $464 · 2024: $506 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.46 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $990.47 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $691.97 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $653.51 | 2019-2025 | |
| Pfizer INC. | $497.29 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $466.13 | 2019-2023 | |
| Amgen INC. | $464.14 | 2019-2022 | |
| Abbott Laboratories | $427.09 | 2019-2024 | Jot Dx |
| Abiomed | $312.08 | 2019 | |
| Amarin Pharma, INC. | $206.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.96 | 2019-2021 | |
| Esperion Therapeutics, INC. | $126.54 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $117.66 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.08 | 2023-2025 | Lifevest |
| Medtronic, INC. | $77.57 | 2022-2024 | Reveal Linq |
| E.R. Squibb & Sons, L.L.C. | $74.41 | 2019-2024 | Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $66.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $56.17 | 2022-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $55.12 | 2019 | |
| Boston Scientific Corporation | $34.85 | 2020-2024 | Watchman Flx |
| Tactile Systems Technology INC | $24.00 | 2020 | |
| Heartflow, INC. | $20.42 | 2022 | |
| Vital Connect, INC | $17.75 | 2025 | Vitalpatch Rtm |
| Lilly USA, LLC | $17.22 | 2022 | |
| Gilead Sciences, INC. | $17.00 | 2019 | |
| Chiesi USA, INC. | $15.45 | 2019 | |
| Baxter Healthcare | $15.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ordonez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.